Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1:2025:1682546.
doi: 10.1155/carj/1682546. eCollection 2025.

The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review

Affiliations

The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review

Khaled S Al Oweidat et al. Can Respir J. .

Abstract

Systemic sclerosis (SSc) is predominantly characterized by an array of cutaneous manifestations including Raynaud's phenomenon, calcinosis, telangiectasias, and skin fibrosis contributing toward substantial morbidity and diminished quality of life. The monumental impact of the disease regarding mortality is due to its pulmonary involvement known as SSc-associated interstitial lung disease (SSc-ILD). Currently, treatment is chiefly directed toward impeding disease progression with the mainstay treatment approaches involving the utilization of cyclophosphamide, mycophenolate mofetil, rituximab, and tocilizumab. Recently, a tyrosine kinase inhibitor, nintedanib, has been approved for the treatment of SSc-ILD and thus became the first medication to be fully licensed for SSc-ILD. A systematic review based on the Preferred Reporting Items of Systematic Review with Meta-analysis (PRISMA) was conducted after successful registration in PROSPERO to evaluate the efficacy and safety of nintedanib in SSc-ILD. We searched PubMed, Scopus, and CENTRAL up to the first of September 2023 utilizing the following keywords: ((Diffuse Parenchymal Lung Disease) OR (Diffuse Parenchymal Lung Diseases) OR (Interstitial Lung Disease) OR (Interstitial Lung Diseases) OR (Interstitial Pneumonia) OR (Interstitial Pneumonitis) OR (Pulmonary Fibrosis)) AND ((Systemic Scleroderma) OR (Systemic Scleroderma)) AND ((BIBF 1120) OR (BIBF-1120) OR (BIBF1120) OR (Nintedanib esylate) OR (Ofev) OR (Vargatef)). The clinical safety profile of nintedanib was deemed more favorable than other therapeutic regimens currently utilized, in addition to adequate clinical efficacy toward SSc-ILD.

Keywords: autoimmune lung disease; scleroderma; systemic sclerosis; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.

Similar articles

References

    1. Denton C. P., Khanna D. Systemic Sclerosis. The Lancet . 2017;390(10103):1685–1699. doi: 10.1016/S0140-6736(17)30933-9. - DOI - PubMed
    1. Van Den Hoogen F., Khanna D., Fransen J., et al. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Annals of the Rheumatic Diseases . 2013;72(11):1747–1755. doi: 10.1136/annrheumdis-2013-204424. - DOI - PubMed
    1. Wells A. U. Interstitial Lung Disease in Systemic Sclerosis. La Presse Médicale . 2014;43(10):e329–e343. doi: 10.1016/j.lpm.2014.08.002. - DOI - PubMed
    1. Perelas A., Silver R. M., Arrossi A. V., Highland K. B. Systemic Sclerosis-Associated Interstitial Lung Disease. The Lancet Respiratory Medicine . 2020;8(3):304–320. doi: 10.1016/S2213-2600(19)30480-1. - DOI - PubMed
    1. Tyndall A. J., Bannert B., Vonk M., et al. Causes and Risk Factors for Death in Systemic Sclerosis: A Study From the EULAR Scleroderma Trials and Research (EUSTAR) Database. Annals of the Rheumatic Diseases . 2010;69(10):1809–1815. doi: 10.1136/ard.2009.114264. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources